-

Silence Therapeutics to Participate in September Investment Conferences

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that company management will participate in the following conferences:

  • Morgan Stanley Global Healthcare Conference, New York
    Fireside chat on Tuesday, September 13, 2022 at 5:15 p.m. ET
  • H.C. Wainwright Global Investment Conference, New York
    Fireside Chat on Wednesday, September 14, 2022 at 4:00 p.m. ET

Webcasts of the fireside chats can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com.

About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence’s proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence’s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address rare hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.

Contacts

Enquiries:
Silence Therapeutics plc
Gem Hopkins, Head of IR and Corporate Communications
ir@silence-therapeutics.com
+1 (646) 637-3208

Industry:

Silence Therapeutics plc

NASDAQ:SLN
Details
Headquarters: London, United Kingdon
CEO: Craig Tooman
Employees: 120
Organization: PUB
Release Versions
English
$Cashtags
$SLN
Hashtags
#SenseofSilence

Contacts

Enquiries:
Silence Therapeutics plc
Gem Hopkins, Head of IR and Corporate Communications
ir@silence-therapeutics.com
+1 (646) 637-3208

Social Media Profiles
Silence Therapeutics Plc
More News From Silence Therapeutics plc

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, (Nasdaq: SLN), (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS, which inc...

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc (“Silence” or the “Company”) , a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has priced its previously announced underwritten public offering of 12,962,963 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS. In addition, Silence...

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has commenced an underwritten public offering of approximately $150 million of its American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States. The proposed offering is a public offering registered under th...
Back to Newsroom